BeiGene
BGNE
#926
Rank
NZ$36.32 B
Marketcap
$323.73
Share price
-2.10%
Change (1 day)
3.87%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Market capitalization of BeiGene (BGNE)

Market cap: NZ$36.32 Billion

As of November 2024 BeiGene has a market cap of NZ$36.32 Billion. This makes BeiGene the world's 926th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of BeiGene from 2016 to 2024

End of year Market Cap

Year Marketcap Change
2024NZ$36.32 B15.92%
2023NZ$31.33 B-15.2%
2022NZ$36.95 B-8.18%
2021NZ$40.24 B20.84%
2020NZ$33.30 B118.01%
2019NZ$15.27 B22.94%
2018NZ$12.42 B98.29%
2017NZ$6.26 B260.33%
2016NZ$1.73 B

End of Day market cap according to different sources

On Nov 17th, 2024 the market cap of BeiGene was reported to be:

NZ$36.32 Billion
by Yahoo Finance info icon info icon
NZ$36.01 Billion
by CompaniesMarketCap info icon info icon
NZ$34.51 Billion
by Nasdaq info icon info icon

Market capitalization for similar companies or competitors

Name Marketcap Market cap differencediff. Country
NZ$35.76 M-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.91 B-94.73%๐Ÿ‡บ๐Ÿ‡ธ USA